Warning Letter to GHMedical.com/Darin Grey

May 4, 2006

Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration


Florida District
555 Winderley Pl, Ste 200
Maitland, FL 32751

June 29, 2002

Darin Grey
1250 E. Hallandale Beach Blvd, Penthouse A
Hallandale, FL 33009


442 Sunset Dr
Hallandale, FL 33009

Ref. No. FLA-02-54

Dear Mr Grey:

This letter concerns Saizen 5 mg, 15 IU [somatropin (rDNA origin) for injection] also known as recombinant human growth hormone (HGH) which is currently marketed by your firm as shown on your Internet site www.gmedical.com. According to information on this site, Saizen is being promoted as part of an anti-aging treatment regimen. Ordering instructions for the drug are provided on the site.

The intended anti-aging treatment use for Saizen is conveyed through claims on your Internet site. These include statements such as “… Saizen … Looking and feeling younger … Saizen may also be used for hormone rejuvenation therapy … Benefits gradually occur over a six to twelve month period … Benefits of HGH … include… 15% average decrease in fat … 8% average increase in muscle and lean body structure … improved skin texture… decrease skin wrinkles … greater bone density… increased time for healing … increased immunity and resistance to infection … increased libido … increase in both energy and strength … improvement of sleep pattern … increase of cardiac output and kidney function … HGH is known to many as the one and only hormone replacement with the capabilities of reversing the biological age…”

Saizen is a “drug” as defined by 21 USC 321(g). Saizen has a new drug application (NO19-764) approved by FDA. Saizen is approved for one indication only, namely for the long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone. The conditions recommended or suggested for the Saizen sold through your website such as hormone rejuvenation therapy and reversing the biological age, among others, render it a “new drug” as defined by 21 USC 321(p). Under 21 USC 355(a), a “new drug” may not be introduced or delivered for introduction into interstate commerce unless an FDA-approved new drug application (NDA) is in effect for such drug. The continued distribution of this product without an approved NDA violates 21 USC 355.

In addition, your Saizen is misbranded under 21 USC 352(f)(1) because its labeling fails to bear adequate directions for the uses for which it is being offered and it is not exempt from this requirement under 21 CFR section 201.115 since it is an unapproved new drug.

Finally, distribution of your HGH product violates 21 USC 3330. Saizen is being promoted and distributed on your website for an unapproved use. There are no recombinant HGH products that are approved by the Food and Drug Administration (FDA) for anti-aging treatment. 21 USC 333(e) states that “…whoever knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition, where such use has been authorized by the Secretary of Health and Human Services under 21 USC 355 and pursuant to the order of a physician, is guilty of an offense punishable by not more than 5 years in prison, such fines as are authorized by Title 18, United States Code, or both.”

This letter is not intended to be an all-inclusive review of your Internet sites, and the products your firm may market. The violations of the Act described above are not intended to be an all-inclusive list of the deficiencies of you and your firm. It is your responsibility to ensure that all drug products manufactured and distributed by your firm are in compliance with Federal laws and regulations. Federal agencies are advised of the issuance of all warning letters about drugs and devices so that they may take this information into account when considering the award of contracts.

You should take prompt action to correct these deviations. Failure to promptly correct these deviations may result in regulatory action without further notice. Possible actions include seizure, injunction, and/or prosecution.

We request that you reply in writing within fifteen (15) days of your receipt of this letter stating the action your firm will take to discontinue marketing of this drug product. Your response should be directed to Martin E. Katz, Compliance Officer, at the Food and Drug Administration, Florida District, 555 Winderley Pl, Ste 200, Maitiand, FL 32751, telephone number 407-475-4729.

Emma R. Singleton
District Director

This page was posted on May 4, 2006.